Scientific Industries to Host Third Quarter Fiscal Year 2025 Financial Results Investor Call on November 20, 2025

Scientific Industries, Inc. (OTCQB: SCND), a company specializing in bioprocessing products and vision-based pill counters, has announced plans to host a conference call on November 20, 2025, at 11:00 a.m. Eastern Time to discuss its financial results for the third quarter of fiscal year 2025. This follows the filing of its Form 10Q and a press release on November 19, 2025, detailing the financial outcomes for the period ending September 30, 2025.

The conference call will be accessible to all interested parties by dialing (844) 481-2706 (domestic) or (412) 317-0662 (international). Additionally, a live webcast option is available on the company’s Investor Relations webpage. For those unable to attend the live session, a replay will be offered until November 27, 2025, through a designated number or on the company's website for 30 days following the event.

Scientific Industries, which markets bioprocessing systems under the DOTS brand and pill counters under the VIVID brand, primarily serves laboratories, hospitals, pharmaceutical firms, and pharmacies. Their product offerings reflect a focus on simplifying bioprocessing through digital innovations, catering to the evolving needs of scientific institutions.

The company included a Safe Harbor statement, indicating that statements regarding future performance are forward-looking and entail uncertainties that may affect actual results. Investors and stakeholders are urged to consider this alongside additional risk factors detailed in the company's SEC filings.

For further information, interested parties may visit their product-specific websites or contact the company directly, including through CEO Helena R. Santos and Lytham Partners for investor inquiries.

As Scientific Industries, Inc. (OTCQB: SCND) approaches its third quarter fiscal year 2025 financial results release, scheduled for November 19, 2025, and a subsequent investor call on November 20, investors should closely monitor several key aspects that may influence stock performance.

With its focus on bioprocessing systems like DOTS and vision-based pill counters under the VIVID brand, Scientific Industries operates in a growing sector propelled by advancements in biotechnology and digitization in healthcare. The demand for automated solutions in laboratories, particularly due to an emphasis on efficiency and accuracy, positions the company favorably within its niche.

Analysts should pay careful attention to the financial results, especially revenue growth and profitability metrics compared to prior quarters. A positive trajectory in earnings could support a bullish outlook, particularly if driven by strong demand across customer segments, including universities, hospitals, and pharmacies. However, if results reveal stagnation or a decline, it may raise concerns about competition and market saturation.

Moreover, the forward-looking statements accompanying the press release suggest a level of optimism, yet they underscore the inherent uncertainties in the biotech sector. Investors should assess management's commentary during the call regarding expected market trends and any strategic initiatives aimed at expanding their market presence.

Key performance indicators such as gross margins and R&D investments will also be critical. High R&D expenditures may indicate a commitment to innovation, but investors must balance this against the need for profitability in the near term.

In conclusion, while Scientific Industries presents several strengths, potential investors should approach the situation with caution. Keeping an eye on the financial results, management insights, and broader market conditions will be paramount in making informed decisions.